investor login
contact
team
dedicated funds
news
portfolio
Discover the
Latest
browse by categories
hatteras venture partner news
Portfolio Company News
Hatteras blogs
browse by categories
Search for:
Portfolio Company News
Contego Medical Announces Unprecedented 30-day Outcomes From The PERFORMANCE III TCAR-IEP Study
November 6, 2025
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
August 7, 2025
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
May 23, 2025
Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
May 7, 2025
Atsena gets Bain’s support in $150M Series C to thwart blindness with gene therapy
April 2, 2025
Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow
April 2, 2025
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
January 13, 2025
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
January 8, 2025
HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform
August 15, 2024
Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes
June 25, 2024
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
July 25, 2023
Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline
May 18, 2023
NewYork-Presbyterian Enrolls First Patient in National Study of Sacral Nerve Stimulation Device for Inflammatory Bowel Disease
May 3, 2023
Cardiosense, Inc., Completes $15.1 Million Series A Financing to Advance Artificial Intelligence Platform for Heart Disease
December 8, 2022
Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery
September 19, 2022
Qvella FAST System and FAST-PBC Prep Cartridge Get CE Marked and FDA Listed for In Vitro Diagnostic Use
April 25, 2022
Huma.AI Adds Post-Market Surveillance Capacity to its Unique AI-Based Healthcare Data Knowledge Platform
February 7, 2022
Aledade Acquires Advance Care Planning Company Iris Healthcare as Part of New Health Services Arm
January 25, 2022
VIGIL NEUROSCIENCE ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
January 7, 2022
Tune Therapeutics Debuts with $40 Million to Fine-Tune the Human Genome
December 3, 2021
Morgan Stanley Expansion Capital and Ally Bridge Group Lead $135 Million Investment in Elligo
September 23, 2021
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
August 18, 2021
CVRx, Inc. Announces Upsized Pricing of Initial Public Offering
June 30, 2021
RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy
June 23, 2021
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
June 16, 2021
Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy
June 1, 2021
CROs dMed and Clinipace Merge to Accelerate Customer Success
April 28, 2021
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
March 2, 2021
FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression
February 18, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
February 18, 2021
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs
October 1, 2020
Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
August 21, 2020
Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies
August 19, 2020
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
August 14, 2020
Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients
July 9, 2020
Shattuck Labs Announces Closing of $118 Million Series B Financing
June 15, 2020
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
May 27, 2020
AtaCor Medical Secures $25M Financing to Continue Extracardiac Pacing Development
April 28, 2020
Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal Diseases
April 23, 2020
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
March 12, 2020
HealthStream Acquires NurseGrid, #1 Rated and Top Downloaded App for Nurses
March 12, 2020
Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting
February 28, 2020
PhaseBio Announces European Regulatory Update for PB2452
February 11, 2020
Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
February 10, 2020
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
January 10, 2020
BioSpace.com selects Qpex to be among Top Life Science Companies to Watch in 2020
January 6, 2020
HistoSonics Robotic Sonic Beam Therapy Platform Wins 2019 Frost & Sullivan Innovation Award
January 6, 2020
Alkermes to Acquire Rodin Therapeutics
November 18, 2019
Sarepta pays StrideBio $48M for preclinical gene therapies
November 15, 2019
NextGen Healthcare Announces Agreement to Acquire Medfusion, Inc.
November 13, 2019
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery
October 30, 2019
410 Medical Secures $8 Million in Series A Financing, Expands Board of Directors
October 22, 2019
Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China
October 22, 2019
A twisty career path to improve care for smokers
October 11, 2019
Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration
October 4, 2019
VERTEX AND RIBOMETRIX ESTABLISH STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP RNA-TARGETED SMALL MOLECULE THERAPEUTICS
September 30, 2019
Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion
September 18, 2019
Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs
August 20, 2019
GeneCentric Therapeutics Acquires Select ImmunoGenomics
August 20, 2019
Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases
July 16, 2019
G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
June 18, 2019
Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting
June 13, 2019
Artizan Biosciences Announces Corporate Progress and Financing
June 11, 2019
Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases
May 15, 2019
Elligo Health Research Raises $20M to Connect More Physicians and Their Patients to Clinical Research as a Care Option
May 7, 2019
Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections
April 30, 2019
G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020
April 30, 2019
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy
April 9, 2019
StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases
March 28, 2019
Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session
March 18, 2019
Mycovia Pharmaceuticals Initiates Additional Phase 3 Clinical Study Evaluating VT-1161 for the Treatment of Vulvovaginal Candidiasis
February 27, 2019
Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis
February 5, 2019
Standard Bariatrics Names Kurt Azarbarzin as Chairman of the Board of Directors
January 30, 2019
HistoSonics Selected as One of the Hottest Startups at the 2019 J.P. Morgan Healthcare Investment Conference
January 8, 2019
Ribometrix raises $30M to drug upstream RNA with small molecules
November 13, 2018
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
November 13, 2018
Qpex Biopharma Announces Closing of $33 Million Series A Financing and Launch of Company to Address Worldwide Problem of Drug-Resistant Infections
October 25, 2018
Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer
October 25, 2018
G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
October 22, 2018
G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
July 9, 2018
Standard Bariatrics closes Series A round of financing
April 18, 2018
Elligo Health Research Raises $16M to Improve Access to Clinical Trials
March 20, 2018
Wildflower Health Receives $8 Million Capital Investment in Funding Round Led by Health Enterprise Partners
March 13, 2018
Clearside Announces Pricing of Public Offering of Common Stock
March 7, 2018
G1 Therapeutics Announces Pricing of Offering of Common Stock
March 7, 2018
Press Ganey Expands Real-Time Data Collection Capabilities Through Acquisition of Bivarus
January 16, 2018
Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-going Research, Team Expansion, and Manufacturing Buildup
December 4, 2017
G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer
November 28, 2017
Ribometrix Raises $7.5 Million in Seed Funding to Advance Platform for Discovering and Developing Small Molecule Modulators of RNA to Treat Human Diseases
October 31, 2017
Rodin Therapeutics Advances Synaptic Resilience Strategy With $27 Million In Financing And Expands Board Of Directors
September 18, 2017
Veritas Genetics Acquires Curoverse to Deploy Large-Scale Artificial Intelligence and Machine Learning in Genomics
August 4, 2017
HistoSonics Technology’s Exciting Preclinical Results to be Presented at the World Conference on Interventional Oncology (WCIO) 2017
June 7, 2017
G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
May 30, 2017
G1 Therapeutics Announces Pricing of Initial Public Offering
May 16, 2017
NeuroTronik Announces $23.1 Million Series B Preferred Stock Financing
April 18, 2017
Bivarus Raises $4 Million to Fuel Continued Growth
March 24, 2017
Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis
January 18, 2017
Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis
January 6, 2017
Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis
January 6, 2017
G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer
December 5, 2016
Older Posts >
contact
team
dedicated funds
news
home
portfolio
